Key examination findings with cholestatic jaundice as an early manifestation led to suspicion of type 4 Farber disease. Observation of hydrocephalus, hypertension, bilateral pinguecula and Erlenmeyer ...

A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease. This extremely rare genetic disorder results in the ...

Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus. The combination gives ...

Dana-Farber is supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the generous support of numerous foundations and individuals who ...

A key research focus at Dana-Farber is finding ways to improve adjuvant therapies and stave off recurrence. To investigate the use of celecoxib on disease-free survival in patients with stage 3 ...